APA (7th ed.) Citation

M, L., M, C., Y, B., Jd, L., DF, A., MR, G., . . . LE, F. (2010). Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert opinion on biological therapy, 10(2), 153. https://doi.org/10.1517/14712590903443084

Chicago Style (17th ed.) Citation

M, Labrada, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, Veloso RC, Vérez V, and Fernández LE. "Direct Validation of NGcGM3 Ganglioside as a New Target for Cancer Immunotherapy." Expert Opinion on Biological Therapy 10, no. 2 (2010): 153. https://doi.org/10.1517/14712590903443084.

MLA (9th ed.) Citation

M, Labrada, et al. "Direct Validation of NGcGM3 Ganglioside as a New Target for Cancer Immunotherapy." Expert Opinion on Biological Therapy, vol. 10, no. 2, 2010, p. 153, https://doi.org/10.1517/14712590903443084.